全文获取类型
收费全文 | 2575篇 |
免费 | 182篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 73篇 |
妇产科学 | 50篇 |
基础医学 | 376篇 |
口腔科学 | 75篇 |
临床医学 | 256篇 |
内科学 | 704篇 |
皮肤病学 | 11篇 |
神经病学 | 225篇 |
特种医学 | 71篇 |
外科学 | 257篇 |
综合类 | 44篇 |
一般理论 | 2篇 |
预防医学 | 224篇 |
眼科学 | 64篇 |
药学 | 159篇 |
肿瘤学 | 143篇 |
出版年
2021年 | 27篇 |
2020年 | 24篇 |
2019年 | 33篇 |
2018年 | 49篇 |
2017年 | 29篇 |
2016年 | 34篇 |
2015年 | 24篇 |
2014年 | 67篇 |
2013年 | 82篇 |
2012年 | 120篇 |
2011年 | 132篇 |
2010年 | 60篇 |
2009年 | 78篇 |
2008年 | 105篇 |
2007年 | 88篇 |
2006年 | 90篇 |
2005年 | 94篇 |
2004年 | 85篇 |
2003年 | 102篇 |
2002年 | 107篇 |
2001年 | 59篇 |
2000年 | 65篇 |
1999年 | 68篇 |
1998年 | 25篇 |
1997年 | 31篇 |
1996年 | 21篇 |
1994年 | 21篇 |
1993年 | 21篇 |
1992年 | 57篇 |
1991年 | 68篇 |
1990年 | 60篇 |
1989年 | 77篇 |
1988年 | 60篇 |
1987年 | 73篇 |
1986年 | 56篇 |
1985年 | 49篇 |
1984年 | 48篇 |
1983年 | 33篇 |
1982年 | 21篇 |
1981年 | 25篇 |
1980年 | 25篇 |
1979年 | 41篇 |
1978年 | 37篇 |
1977年 | 35篇 |
1976年 | 18篇 |
1975年 | 17篇 |
1974年 | 29篇 |
1972年 | 22篇 |
1970年 | 21篇 |
1969年 | 18篇 |
排序方式: 共有2763条查询结果,搜索用时 15 毫秒
71.
72.
Mead AJ Gale RE Kottaridis PD Matsuda S Khwaja A Linch DC 《British journal of haematology》2008,141(4):454-460
FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis. Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level. We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+). All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact. FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004). There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells. Synergistic cytotoxicity of lestaurtinib plus cytarabine was demonstrated in all three groups. These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors. 相似文献
73.
74.
75.
Richard A Brogan Christopher J Malkin Philip D Batin Alexander D Simms James M McLenachan Christopher P Gale 《World journal of cardiology》2014,6(8):865-873
Acute coronary syndromes presenting with ST elevation are usually treated with emergency reperfusion/revascularisation therapy. In contrast current evidence and national guidelines recommend risk stratification for non ST segment elevation myocardial infarction(NSTEMI) with the decision on revascularisation dependent on perceived clinical risk. Risk stratification for STEMI has no recommendation. Statistical risk scoring techniques in NSTEMI have been demonstrated to improve outcomes however their uptake has been poor perhaps due to questions over their discrimination and concern for application to individuals who may not have been adequately represented in clinical trials. STEMI is perceived to carry sufficient risk to warrant emergency coronary intervention [by primary percutaneous coronary intervention(PPCI)] even if this results in a delay to reperfusion with immediate thrombolysis. Immediate thrombolysis may be as effective in patients presenting early, or at low risk, but physicians are poor at assessing clinical and procedural risks and currently are not required to consider this. Inadequate data on risk stratification in STEMI inhibits the option of immediate fibrinolysis, which may be cost-effective. Currently the mode of reperfusion for STEMI defaults to emergency angiography and percutaneous coronary intervention ignoring alternative strategies. This review article examines the current risk scores and evidence base for risk stratification for STEMI patients. The requirements for an ideal STEMI risk score are discussed. 相似文献
76.
Graham SM Ahmed T Amanullah F Browning R Cardenas V Casenghi M Cuevas LE Gale M Gie RP Grzemska M Handelsman E Hatherill M Hesseling AC Jean-Philippe P Kampmann B Kabra SK Lienhardt C Lighter-Fisher J Madhi S Makhene M Marais BJ McNeeley DF Menzies H Mitchell C Modi S Mofenson L Musoke P Nachman S Powell C Rigaud M Rouzier V Starke JR Swaminathan S Wingfield C 《The Journal of infectious diseases》2012,205(Z2):S199-S208
There is a critical need for improved diagnosis of tuberculosis in children, particularly in young children with intrathoracic disease as this represents the most common type of tuberculosis in children and the greatest diagnostic challenge. There is also a need for standardized clinical case definitions for the evaluation of diagnostics in prospective clinical research studies that include children in whom tuberculosis is suspected but not confirmed by culture of Mycobacterium tuberculosis. A panel representing a wide range of expertise and child tuberculosis research experience aimed to develop standardized clinical research case definitions for intrathoracic tuberculosis in children to enable harmonized evaluation of new tuberculosis diagnostic technologies in pediatric populations. Draft definitions and statements were proposed and circulated widely for feedback. An expert panel then considered each of the proposed definitions and statements relating to clinical definitions. Formal group consensus rules were established and consensus was reached for each statement. The definitions presented in this article are intended for use in clinical research to evaluate diagnostic assays and not for individual patient diagnosis or treatment decisions. A complementary article addresses methodological issues to consider for research of diagnostics in children with suspected tuberculosis. 相似文献
77.
Lown MT Munyombwe T Harrison W West RM Hall CA Morrell C Jackson BM Sapsford RJ Kilcullen N Pepper CB Batin PD Hall AS Gale CP;Evaluation of Methods Management of Acute Coronary Events 《The American journal of cardiology》2012,109(3):307-313
Risk assessment is central to the management of acute coronary syndromes. Often, however, assessment is not complete until the troponin concentration is available. Using 2 multicenter prospective observational studies (Evaluation of Methods and Management of Acute Coronary Events [EMMACE] 2, test cohort, 1,843 patients; and EMMACE-1, validation cohort, 550 patients) of unselected patients with acute coronary syndromes, a point-of-admission risk stratification tool using frontal QRS-T angle derived from automated measurements and age for the prediction of 30-day and 2-year mortality was evaluated. Two-year mortality was lowest in patients with frontal QRS-T angles <38° and highest in patients with frontal QRS-T angles >104° (44.7% vs 14.8%, p <0.001). Increasing frontal QRS-T angle-age risk (FAAR) scores were associated with increasing 30-day and 2-year mortality (for 2-year mortality, score 0 = 3.7%, score 4 = 57%; p <0.001). The FAAR score was a good discriminator of mortality (C statistics 0.74 [95% confidence interval 0.71 to 0.78] at 30 days and 0.77 [95% confidence interval 0.75 to 0.79] at 2 years), maintained its performance in the EMMACE-1 cohort at 30 days (C statistics 0.76 (95% confidence interval 0.71 to 0.8] at 30 days and 0.79 (95% confidence interval 0.75 to 0.83] at 2 years), in men and women, in ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, and compared favorably with the Global Registry of Acute Coronary Events (GRACE) score. The integrated discrimination improvement (age to FAAR score at 30 days and at 2 years in EMMACE-1 and EMMACE-2) was p <0.001. In conclusion, the FAAR score is a point-of-admission risk tool that predicts 30-day and 2-year mortality from 2 variables across a spectrum of patients with acute coronary syndromes. It does not require the results of biomarker assays or rely on the subjective interpretation of electrocardiograms. 相似文献
78.
79.
80.